MediXall cuts costs, converts debt to equity; reports Q3 profit but cash-starved, going-concern

MediXall Group, Inc. (OTCBB: MDXL) - Quick internal read

The company is operating through its active subsidiary Health Karma Inc. Management has cut costs (office move, headcount reductions, outsourcing marketing/IT/UX and sales) and converted large amounts of debt and preferred interest into equity. However the balance sheet still shows a working capital deficit and the auditors/management state substantial doubt about going concern.

Key points & statistics
- Quarter (ended Sept 30, 2024) revenue: $38,858 - down 41% vs Q3 2023 ($65,535).
- Nine months revenue: $209,839 vs $214,925 in 2023 (down 2%).
- Q3 Gross margin: $22,300 (Q3 2023: $2,425). Nine months gross margin: $128,283 (2023: $26,829).
- Q3 Net income: $263,813 vs net loss $908,067 in Q3 2023. Nine months net loss: $(708,649) vs $(3,108,940) in 2023 - improvement of >$2.4M YTD.
- Q3 total operating expenses (net of gain): $(241,513) vs $910,492 in Q3 2023 (large swing driven by a $610,290 gain on settlement of payables).
- Interest expense nine months: $332,248 (2023: $171,837).
- Cash: $31,916 at Sept 30, 2024. Net cash used in operating activities (9 months): $(1,000,828). Net cash provided by financing: $1,022,023.
- Total assets: $219,980. Total liabilities: $3,838,658. Stockholders' deficit: $(3,618,678).
- Accounts payable & accrued expenses: $2,062,550. Accrued dividends (Series B): $1,107,223 (unpaid at 9/30/24).
- Senior convertible debentures, net: $177,500 at 9/30/24 (down from $3,830,277 at 12/31/23 after conversions).
- Weighted average common shares (Q3): 162,270,572. Basic EPS Q3: $0.00; nine months: $(0.01).
- Material non‑cash items: conversion of debentures & accrued interest to common stock - $4,466,882 (non‑cash) during the period; subsequent conversions and stock dividend activity occurred after 9/30/24 (noted Jan 27, 2025 filings).
What's happening inside the company
- Active focus on Health Karma platform; corporate consolidation and outsourcing to cut recurring SG&A.
- Management converted large amounts of debt/interest and Series B preferred claims into equity to reduce on‑balance sheet debt and liabilities.
- Series B preferred dividends accrued ($1,107,223) and were later paid in common stock (post‑period).
- Internal control weaknesses disclosed: outsourced accounting, insufficient staff, lack of segregation of duties - management labels these as material weaknesses and expects to address when funds permit.
Income statement - positives
- Turnaround in the quarter: Q3 2024 reported net income $263,813 vs a prior-year loss, driven by lower professional fees and a one-time gain on settlement of payables ($610,290).
- Operating expenses fell materially YTD: total operating expense for nine months down ~73% ($836,932 vs $3,135,769), primarily from reduced stock‑based compensation and other professional fees cuts.
- Gross margins improved materially both for the quarter and year-to-date despite lower revenue - indicates better variable cost control on services sold.
Income statement - negatives
- Revenue decline in Q3 (-41%) tied to a key client pausing their program (April-Sept 2024). That client concentration risk is material to near-term top line.
- Interest expense increased ($332,248 YTD) and accrued interest on convertible debentures was substantial (accrued interest payable $890,143 at 9/30/24).
- Net income improvement is partially attributable to non-recurring items (gain on settlement, large debt-to-equity conversions) - not all cash‑generating improvements.
- Still a cumulative accumulated deficit of $38,992,083 and a net working capital deficit of $3,746,084 - severe balance sheet strain.
Risks & near-term watches
- Cash runway is very limited: $31,916 cash and ongoing operating cash burn - company depends on additional financing or client revenue restart.
- High dilution risk: conversions of preferred shares, debentures and outstanding warrants create significant potential share issuance (management already converted large amounts).
- Internal control and accounting weaknesses could affect reporting and capital raising until remediated.
- Client concentration: recovery of the paused program and new client wins are required to stabilize revenue trends.

Bottom line: management has aggressively cut costs and engineered debt-to-equity conversions - producing a better quarterly operating result - but the company remains cash‑starved, balance‑sheet weak, and dependent on financing or recurring revenue recovery. Monitor cash, client program restarts, and any future equity raises (dilution).